Strong September auto sales lifted the markets to a higher close with the Dow climbing 84 points to 22,641. Nasdaq rose 15 points to 6,531.

On the upside

Endocyte (Nasdaq: ECYT) entered an exclusive worldwide license for PSMA-617 and will begin Phase 3 development of Lu-PSMA-617 to treat prostate cancer.

The Food and Drug Administration approved an update to MannKind's (Nasdaq: MNKD) Afrezza prescribing information.

Fairmount Santrol (NYSE: FMSA) may be acquired by SCR-Sibelco.

On the downside

Tile Shop Holdings (Nasdaq: TTS) warned that third quarter revenue would fall short of expectations.

Profit taking weighed down shares of Aralez Pharmaceuticals (Nasdaq: ARLZ).

Investors locked in profits on Roku (Nasdaq: ROKU).

In the broad market, declining issues outpaced advancers by a margin of nearly 4 to 3 on the NYSE and by 6 to 5 on Nasdaq. The broader S&P 500 rose 5 points to 2,534. Bitcoin tumbled $85 to $4,286.